113 related articles for article (PubMed ID: 16723233)
1. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.
Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA
Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the activity of the RSK-specific inhibitor, SL0101.
Smith JA; Maloney DJ; Hecht SM; Lannigan DA
Bioorg Med Chem; 2007 Jul; 15(14):5018-34. PubMed ID: 17512736
[TBL] [Abstract][Full Text] [Related]
3. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
4. Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.
Hilinski MK; Mrozowski RM; Clark DE; Lannigan DA
Bioorg Med Chem Lett; 2012 May; 22(9):3244-7. PubMed ID: 22464132
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of a potent and selective inhibitor of p90 Rsk.
Maloney DJ; Hecht SM
Org Lett; 2005 Mar; 7(6):1097-9. PubMed ID: 15760148
[TBL] [Abstract][Full Text] [Related]
6. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA
Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840
[TBL] [Abstract][Full Text] [Related]
7. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
8. Three acetylated flavonol glycosides from Forsteronia refracta that specifically inhibit p90 RSK.
Xu YM; Smith JA; Lannigan DA; Hecht SM
Bioorg Med Chem; 2006 Jun; 14(11):3974-7. PubMed ID: 16524738
[TBL] [Abstract][Full Text] [Related]
9. Improving the affinity of SL0101 for RSK using structure-based design.
Mrozowski RM; Vemula R; Wu B; Zhang Q; Schroeder BR; Hilinski MK; Clark DE; Hecht SM; O'Doherty GA; Lannigan DA
ACS Med Chem Lett; 2012 Feb; 4(2):175-179. PubMed ID: 23519677
[TBL] [Abstract][Full Text] [Related]
10. Regioselective Synthesis of a
Li Y; Sandusky ZM; Vemula R; Zhang Q; Wu B; Fukuda S; Li M; Lannigan DA; O'Doherty GA
Org Lett; 2020 Feb; 22(4):1448-1452. PubMed ID: 32009414
[TBL] [Abstract][Full Text] [Related]
11. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.
Utepbergenov D; Derewenda U; Olekhnovich N; Szukalska G; Banerjee B; Hilinski MK; Lannigan DA; Stukenberg PT; Derewenda ZS
Biochemistry; 2012 Aug; 51(33):6499-510. PubMed ID: 22846040
[TBL] [Abstract][Full Text] [Related]
12. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
13. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
[TBL] [Abstract][Full Text] [Related]
14. Divergent off-target effects of RSK N-terminal and C-terminal kinase inhibitors in cardiac myocytes.
Stathopoulou K; Schobesberger S; Bork NI; Sprenger JU; Perera RK; Sotoud H; Geertz B; David JP; Christ T; Nikolaev VO; Cuello F
Cell Signal; 2019 Nov; 63():109362. PubMed ID: 31344438
[TBL] [Abstract][Full Text] [Related]
15. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.
Neise D; Sohn D; Stefanski A; Goto H; Inagaki M; Wesselborg S; Budach W; Stühler K; Jänicke RU
Cell Death Dis; 2013 Oct; 4(10):e859. PubMed ID: 24136223
[TBL] [Abstract][Full Text] [Related]
16. Identifying requirements for RSK2 specific inhibitors.
Wright EB; Fukuda S; Li M; Li Y; O'Doherty GA; Lannigan DA
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1798-1809. PubMed ID: 34348556
[TBL] [Abstract][Full Text] [Related]
17. Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.
Derewenda U; Artamonov M; Szukalska G; Utepbergenov D; Olekhnovich N; Parikh HI; Kellogg GE; Somlyo AV; Derewenda ZS
Acta Crystallogr D Biol Crystallogr; 2013 Feb; 69(Pt 2):266-75. PubMed ID: 23385462
[TBL] [Abstract][Full Text] [Related]
18. De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101.
Mrozowski RM; Sandusky ZM; Vemula R; Wu B; Zhang Q; Lannigan DA; O'Doherty GA
Org Lett; 2014 Nov; 16(22):5996-9. PubMed ID: 25372628
[TBL] [Abstract][Full Text] [Related]
19. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
20. Paving the way for targeting RSK in cancer.
Romeo Y; Roux PP
Expert Opin Ther Targets; 2011 Jan; 15(1):5-9. PubMed ID: 20958120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
